Possible role of α-adrenoceptor subtypes in acute migraine therapy

Cephalalgia

Volumn 23, Issue 4, 2003, Pages 245-257

  Willems, E W ^a   Valdivia, L F ^b   Villalon C M ^b   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

adrenoceptor subtypes; Adrenoceptors; Carotid vascular bed; Experimental models; Migraine

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 4 AMINO 2 [4 BENZYLOXYCARBONYL 3 [(TERT BUTYLAMINO)CARBONYL] 1 PIPERAZINYL] 6,7 DIMETHOXYQUINAZOLINE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 METHYLURAPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIMIGRAINE AGENT; AZEPEXOLE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; IMILOXAN; LANEPITANT; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N(G) METHYLARGININE; NEUROKININ 1 RECEPTOR ANTAGONIST; PHENYLEPHRINE; PNU 142633; PRAZOSIN; RAUWOLSCINE; SEROTONIN 1D AGONIST; SEROTONIN 1F AGONIST; SUMATRIPTAN; TONABERSAT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BRAIN BLOOD VESSEL; CAROTID ARTERY; CONTROLLED STUDY; DRUG SELECTIVITY; EXPERIMENTAL MODEL; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MIGRAINE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SECOND MESSENGER; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADRENERGIC AGONISTS; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; MIGRAINE DISORDERS; MODELS, ANIMAL; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; VASOCONSTRICTION;

EID: 0038291778     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2003.00547.x     Document Type: Review

References (84)

1. Willems EW. Characterisation of α-adrenoceptor subtypes in the carotid vasculature: possible implications for migraine therapy. PhD Thesis, Rotterdam: Erasmus University Rotterdam, 2001:188.
2. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin 1997; 15:27-42.
3. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2:5-21.
4. Saxena PR. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models, Vol. 27. Philadelphia: Lippincott-Raven, 1995:189-98.
5. De Vries P, Villalón CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375:61-74.
6. Moskowitz MA, Reinhard JF Jr, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979; 2:883-5.
7. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993; 5:159-77.
8. Goadsby PJ. Advances in the pharmacotherapy of migraine. How knowledge of pathophysiology is guiding drug development. Drugs R D 1999; 2:361-74.
9. 1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol 1998; 124:1345-54.
10. 1B/1D, as well as unidentified receptors. In: Edvinsson L, editor. Migraine and headache pathophysiology. London: Martin Dunitz Ltd., 1999:119-32.
11. Wolff HG. Headache and other headpain. New York: Oxford University Press, 1963.
12. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969; 2:1-28.
13. Hales JRS. Radioactive microsphere techniques for studies of the circulation. Clin Exp Pharmacol Physiol 1974; 1:31-46.
14. Van Woerkens LJ, Duncker DJ, Huigen RJ, van der Giessen WJ, Verdouw PD. Redistribution of cardiac output caused by opening of arteriovenous anastomoses by a combination of azaperone and metomidate. Br J Anaesth 1990; 65:393-9.
15. Den Boer MO, Van Woerkens LJ, Somers JA, Duncker DJ, Lachmann B, Saxena PR et al. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 1993; 75:782-9.
16. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
17. Villalón CM, Ramirez-San Juan E, Castillo C, Castillo E, Lopez-Munoz FJ, Terrón JA. Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br J Pharmacol 1995; 116:2778-84.
18. 1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:212-9.
19. Villalón CM, Centurión D, Sánchez-López A, De Vries P, Saxena PR. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomised dogs. Acta Pharmacol Sin 1999; 20:1057-67.
20. 1D receptor antagonist. Br J Pharmacol 1996; 118:85-92.
21. 1D (BRL15572) receptor antagonists. Eur J Pharmacol 1998; 362:69-72.
22. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 2000; 129:501-8.
23. 1D receptor agonist PNU-142633. IBC's Annual Conference on Migraine, Philadelphia, USA, 1999.
24. 1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358:1230-4.
25. Dahlöf CGH, Saxena PR. Novel compounds in development for acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The migraines, 2nd edn. Philadelphia: Lippincott Wiliams & Wilkins, 2000:439-43.
26. May A, Goadsby PJ. Pharmacological opportunities and pitfalls in the therapy of migraine. Curr Opin Neurol 2001; 14:341-5.
27. Hein L, Kobilka BK. Adrenergic receptor signal transduction and regulation. Neuropharmacology 1995; 34:357-66.
28. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948; 153:586-600.
29. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998; 158:S146-S53.
30. Kaumann AJ. Four beta-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 1997; 18:70-6.
31. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51:651-90.
32. Godfraind T, Vanhoutte PM, Ruffolo RR, Humphrey PPA. The IUPHAR compendium of receptor characterzation and classification. Cambridge: IUPHAR Media Ltd, 1998.
33. Alexander SPH, Peter JA. 1999 Receptor and ion channel nomenclature supplement. Trends in Pharmacological Sciences 1999; 20:11-4.
34. Hieble JP. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm Acta Helv 2000; 74:163-71.
35. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46:157-203.
36. Hoyer D, Humphrey PP. Nomenclature and classification of transmitter receptors: an integrated approach. J Recept Signal Transduct Res 1997; 17:551-68.
37. 2-adrenoceptors. Eur J Pharmacol 1998; 361:1-15.
38. 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47:267-70.
39. 1-adrenoceptor subtypes. Eur J Pharmacol 1999; 375:261-76.
40. 1-adrenoceptor subtypes in cells and tissues including human prostate. Eur Urol 1999; 36:42-7; discussion 65.
41. 1-adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci 1995; 57:2291-308.
42. 1-adrenergic receptor subtypes in human tissues: implications for human α-adrenergic physiology. Mol Pharmacol 1994; 45:171-5.
43. 1-adrenergic receptors. Cell Signal 1996; 8:323-33.
44. 1-adrenoceptors in vascular smooth muscle. Mol Pharmacol 1994; 46:30-40.
45. 1B-adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther 1997; 283:854-68.
46. 1b-adrenergic receptor. Proc Natl Acad Sci USA 1997; 94:11589-94.
47. 2-Adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol Sci 1994; 15:119-23.
48. Piascik MT, Soltis EE, Piascik MM, Macmillan LB. α-Adrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates. Pharmacol Ther 1996; 72:215-41.
49. 2-adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. Br J Pharmacol 2001; 133:859-66.
50. 2-adrenoceptors. Biochem Pharmacol 2001; 62:913-22.
51. 2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:634-9.
52. Gavras H, Handy DE, Gavras I. α-Adrenergic receptors in hypertension. In: Laragh JH, Brenner BM, editors. Hypertension, pathophysiology, diagnosis and management. New York: Raven Press, 1995:853-61.
53. 2A-adrenergic receptor subtype. Hypertension 1999; 34:403-7.
54. 2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999; 33:14-7.
55. 2B-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000; 35:609-13.
56. 2B-adrenergic receptor subtypes in brain. Hypertension 1996; 27:449-55.
57. 2A-adrenergic receptor knockout mice. Mol Pharmacol 1999; 56:154-61.
58. 2-adrenergic receptor subtypes b and c. Science 1996; 273:803-5.
59. 2a-adrenergic receptor subtype. Science 1996; 273:801-3.
60. Docherty JR, McGrath JC. A comparison of pre- and post-junctional potencies of several α-adrenoceptor agonists in the cardiovascular system and anococcygeus muscle of the rat. Evidence for two types of post-junctional α-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 1980; 312:107-16.
61. 2-adrenoceptor mediating pressor responses in the pithed rat. Eur J Pharmacol 1996; 318:81-7.
62. Drew GM, Whiting SB. Evidence for two distinct types of postsynaptic α-adrenoceptor in vascular smooth muscle in vivo. Br J Pharmacol 1979; 67:207-15.
63. 2-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. General Pharmacol 2000; 34:101-6.
64. 2-adrenergic receptors in normal and atherosclerotic rabbit aorta. Hypertension 1998; 32:311-7.
65. 2C-Adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 1997; 355:406-11.
66. Kawai Y, Kobayashi S, Ohhashi T. Existence of two types of postjunctional α-adrenoceptors in the isolated canine internal carotid artery. Can J Physiol Pharmacol 1988; 66:655-9.
67. 1-adrenoceptor subtypes in dog mesenteric and carotid arteries and rabbit carotid arteries. Br J Pharmacol 1991; 102:210-4.
68. 1-adrenoceptor subtypes involved in noradrenaline contraction of the rabbit thoracic aorta. Br J Pharmacol 1990; 101:662-6.
69. Ohgushi M, Yasue H, Kugiyama K, Murohara T, Sakaino N. Contraction and endothelium dependent relaxation via α adrenoceptors are variable in various pig arteries. Cardiovasc Res 1993; 27:779-84.
70. Verdouw PD, Duncker DJ, Saxena PR. Poor vasoconstrictor response to adrenergic stimulation in the arteriovenous anastomoses present in the carotid vascular bed of young Yorkshire pigs. Arch Int Pharmacodyn Ther 1984; 272:56-70.
71. 1-adrenoceptors in the reduction of external carotid blood flow induced by buspirone and ipsapirone in the dog. Life Sci 1996; 58:63-73.
72. 2-adrenoceptors. Br J Pharmacol 1999; 126:385-94.
73. 2-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol 2001; 132:1292-8.
74. 2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 1999; 127:1263-71.
75. Willems EW, Valdivia LF, San Juan ER, Saxena PR, Villalón CM. Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline. Life Sci 2001; 69:143-53.
76. Saxena PR, Schamhardt HC, Forsyth RP, Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed 1980; 12:63-84.
77. Saxena PR. Arteriovenous anastomoses and veins in migraine research. In: Blau JN, editor. Migraine, clinical, therapeutic, conceptual and research aspects. London: Chapman & Hall, 1987.
78. 1-adrenoceptor subtypes mediating vasoconstriction in the carotid circulation of anaesthetised pigs; possible avenues for antimigraine drug development. Cephalalgia 2001; 21:110-9.
79. Akerman S, Williamson DJ, Hill RG, Goadsby PJ. The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 2001; 424:53-8.
80. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98:25-30.
81. MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55:1524-30.
82. 1-adrenergic receptors by vessel bed and age. Circulation 1999; 100:2336-43.
83. 2-adrenergic receptor agonists in the rat. Neuroscience 1995; 66:427-32.
84. Bylund DB, Bond RA, Clarke DE, Eikenburg DC, Hieble JP, Langer SZ et al. Adrenoceptors. The IUPHAR compendium of receptor characterization and classification. London: IUPHAR Media, 1998:58-74.